Table 1.

Clinical data for tumor samples

Sample	Sample origin	Patient age (years)/sex	Diagnosis Initial	Revised	Grade1	Location	Size (cm)2	Metastasis (months)3	Status	Follow-up (months)4	Neurofibromatosis
MS1	Prim	71/F	MPNST	MPNST	4	Upper trunk	10	NM	NED	100	+
MS2	Prim	46/M	MPNST	MPNST	4	Lower leg	40	MD	DD	1	+
MS5	Met	24/M	MPNST	MPNST	4	Upper trunk	9	20	DD	163
MS7	Prim	42/M	MPNST	MPNST	4	Pelvic areas	7	6	DD	12
MS8x	Prim	78/F	MPNST	MPNST	4	Gluteal	20	MD	DD	12
MS9x	Rec	26/M	MPNST	MPNST	4	Upper trunk	4	70	DD	79	+
MS13	Prim	40/M	MFH	MPNST5	4	Thigh	10	NM	NED	216	+
BS	Prim	50/M	MPNST	BS	-	Retroperitoneum	7	NM	NED	120
NF	Prim	19/F	MPNST	NF	-	Retroperitoneum	11	185	DD	186

Abbreviations: x, xenograft; Prim, primary tumor; Met, metastasis; Rec, recurrence; F, female; M, male; MFH, malignant fibrous histiocytoma; BS, benign schwannoma; NF, neurofibroma; NM, no metastasis; MD, metastasis at diagnosis; NED, no evidence of disease; DD, dead of disease.

¹ Grading is based on a four-tiered system used in the Scandinavian Sarcoma Group.

² Largest diameter of the tumor.

³ Time to first metastasis from diagnosis.

⁴ Time to last follow-up from diagnosis.

⁵ Pleomorphic sarcoma in a patient with neurofibromatosis.